Bayer Raises Drug Sales Forecast as Quarterly Profit Lags
This article is for subscribers only.
Bayer AG raised its forecast for peak sales of new drugs such as the blood thinner Xarelto even as fourth-quarter results and the revenue outlook for this year missed analyst estimates.
Bayer’s five most important new medicines will reach at least 7.5 billion euros ($10.3 billion) a year in combined revenue, the Leverkusen, Germany-based company said in a statement today. Previously, Bayer predicted 5.5 billion euros.